BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Isconova to Present at "Influenza Vaccines for the World Conference"


10/11/2012 10:59:19 AM

Uppsala, October 11, 2012 -- Isconova AB, a leading international vaccine adjuvant company will be presenting at Influenza Vaccines for the World Conference in Valencia, Spain on October 12th

Karin Lövgren-Bengtsson, Chief Scientific Officer of Isconova will present ‘Clinical and preclinical experience with Isconova’s proprietary adjuvant Matrix-M™’ focusing on the results of clinical studies on Pandemic influenza and seasonal influenza vaccine in elderly with Isconova’s proprietary adjuvant Matrix-M™.

The presentation will take place at day 3, session 11, from 14:00 to 14:20 in Palacio de Congresos De Valencia, Valencia, Spain.

About Isconova

Isconova AB is a leading international vaccine adjuvant company. Isconova has deep knowledge of vaccine systems, and the company develops novel vaccines together with partners in the human and veterinary markets. The first vaccine using Isconova’s Matrix technology was launched in the veterinary market in 2006. In the human vaccine market, a number of vaccines are under development with Isconova’s third generation nano-particle, Matrix-M™. The Company is headquartered in Uppsala, Sweden. For more information, visit www.isconova.com

Contact:

Sven Andréasson, CEO, +46 701 60 60 60,

sven.andreasson@isconova.com



Read at BioSpace.com

   
Influenza

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES